Breast imagingCase Type
González Campo L1, Vicente Zapata I1, Jiménez López A2, Carretero Barrio I3, Pérez Mies B3, Chiva de Agustín M1
59 years, female
A 59-year-old woman with breast implants for augmentation mammoplasty since 2007 came to the Emergency Department with an increase in the size and hardening of her right breast for the last 2 months. No heat, erythema or other signs of local infection in the physical examination. No fever.
Bilateral breast and axillary ultrasound were performed: Bilateral subpectoral implants. Findings were compatible with probable bilateral intracapsular implant rupture (increased intercapsular space, capsule folds and heterogeneous echogenic images). Furthermore, in the right breast, abundant anechoic peri-implant fluid was observed with heterogeneous images (may be debris or capsular components of the prosthesis). No breast mass or axillary lymphadenopathy were associated. Fine-needle aspiration of this liquid was performed, obtaining 40 ccs that we sent to pathological study.
Pathological report: Cytology and immunohistochemical profile (CD30 positive; cytokeratins, CD20, CD3 and ALK-negative) concordant with implant-associated anaplastic large cell lymphoma (BIA-ALCL). Category C5. Radiology-pathology correlation: Appropriate.
The diagnosis was confirmed after implant removal.
MRI was not performed. The expected MRI findings in BIA-ALCL are peri-implant effusions (frequent finding) and/or associated mass (depending on the BIA-ALCL form). Signs of implant rupture with thickening and irregularity are also frequent. Capsular enhancement is occasionally seen. We will also identify suspicious regional lymphadenopathies if they exist.
Body F18-FDG PET-CT didn’t show suspicious findings.
BIA-ALCL is a rare peripheral T-cell lymphoma, classified by WHO as a separate subtype of non-Hodgkin lymphoma. It is a disease of the breast implant capsule . Annual incidence is estimated at 0.1 to 0.3 per 100,000 women with implants  and its exact pathology is not well understood yet.
It carries a good prognosis with a median overall survival rate up to 93% at 3 years and 89% at 5 years  and can arise in two different forms of presentation: In situ (more frequent) or infiltrative disease (palpable mass or lymph nodes involvement). Almost all documented cases of BIA-ALCL have been associated with a textured device, especially those with a higher surface area [4, 5, 6, 7, 8, 9]. No increased risk of lymphoma has been identified in patients with implants after cancer surgery compared to patients with cosmetic implants .
There exist two forms of BIA-ALCL: peri-implant effusion-type and peri-implant mass-type. In the majority of patients (60-90%), it usually presents with unilateral breast swelling caused by a rapid onset of spontaneous fluid collection (seroma). The average onset is 8 -10 years after implantation [1, 3, 5, 10, 11]. Palpable breast mass is less frequent (10-40%) [3, 4, 10]. Lymphadenopathy (20%), skin manifestations and B symptoms (fever, chills, weight loss, etc) can also be present. .
Imaging diagnostic should start with an ultrasound evaluation to identify the presence of seroma, capsular masses or regional lymphadenopathy. Fine-needle aspiration of peri-implant fluid collections should be performed and in case of solid mass, a histologic sample is recommended. To evaluate collections, masses and lymph nodes MRI can be helpful, especially in mass-type lymphomas . Mammography is not considered an acceptable imaging modality . PET is also used to evaluating associated capsular masses, chest wall involvement and systemic spread (lymph nodes) .
The diagnosis requires CD30+ immunohistochemistry, large anaplastic cells on cytology and local expansion on flow cytometry .
A standard of care for the treatment doesn’t exist. For localized disease, in most cases, surgery can be sufficient, (total capsulectomy and removal of the implant in addition to the capsule with negative margins). In cases of advanced disease combinations of chemotherapy are being used . Radiation therapy may be used for local residual or unresectable disease.
For post-treatment surveillance, CT or PET imaging at a maximum of every 6 months for the first 2 years is recommended by NCCN Guidelines .
Written informed patient consent for publication has been obtained.
 Ebner PJ, Liu A, Gould DJ, Patel KM. Breast implant–associated anaplastic large cell lymphoma, a systematic review and in‐depth evaluation of the current understanding. J Surg Oncol. agosto de 2019;jso.25626 (PMID: 31373010)
 de Jong D. Anaplastic Large-Cell Lymphoma in Women With Breast Implants. JAMA. 5 de noviembre de 2008;300(17):2030 (PMID: 18984890)
 DePaola NEK, Coggins H. Breast Implant–Associated Anaplastic Large Cell Lymphoma: What We Know. J Adv Pract Oncol. 2019;10(1):54-61 (PMID: 31308988)
 Marra A, Viale G, Pileri SA, Pravettoni G, Viale G, De Lorenzi F, et al. Breast implant-associated anaplastic large cell lymphoma: A comprehensive review. Cancer Treat Rev. marzo de 2020;84:101963 (PMID: 31958739)
 K Groth A, Graf R. Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) and the Textured Breast Implant Crisis. Aesth Plast Surg. febrero de 2020;44(1):1-12. (PMID: 31624894)
 Kricheldorff J, Maria Fallenberg E, Solbach C, Gerber-Schäfer C, Rancsó C, von Fritschen U. Breast Implant-Associated Lymphoma. Dtsch Arztebl Int. septiembre de 2018;115(38):628-35. (PMID: 30373708)
 Loch-Wilkinson A, Beath KJ, Knight RJW, Wessels WLF, Magnusson M, Papadopoulos T, et al. Breast Implant–Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk. Plastic and Reconstructive Surgery. octubre de 2017;140(4):645-54. (PMID: 28481803)
 Adams WP, Culbertson EJ, Deva AK, R. Magnusson M, Layt C, Jewell ML, et al. Macrotextured Breast Implants with Defined Steps to Minimize Bacterial Contamination around the Device: Experience in 42,000 Implants. Plastic & Reconstructive Surgery. septiembre de 2017;140(3):427-31. (PMID: 28841597)
 Leberfinger AN, Behar BJ, Williams NC, Rakszawski KL, Potochny JD, Mackay DR, et al. Breast Implant–Associated Anaplastic Large Cell Lymphoma: A Systematic Review. JAMA Surg. 1 de diciembre de 2017;152(12):1161. (PMID: 29049466)
 Julien L, Michel RP, Auger M. Breast implant–associated anaplastic large cell lymphoma and effusions: A review with emphasis on the role of cytopathology. Cancer Cytopathology. 3 de enero de 2020;cncy.22233 (PMID: 31899606)
 Rastogi P, Deva AK, Prince HM. Breast Implant-Associated Anaplastic Large Cell Lymphoma. Curr Hematol Malig Rep. diciembre de 2018;13(6):516-24 (PMID: 30345474)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.